“…Details of the pharmacokinetic profile were later reported by Plym Forshell in 1976 2 . It is a tricyclic compound recently introduced for general clinical use, and there are now many reports on efficacy, safety, and liability to fewer side effects than other tricyclics in many open and double‐blind studies in the treatment of depressive states dating back almost 10 years 3–11 . There have been two international symposia on antidepressant drug therapy with particular reference to lofepramine 12 , 13 .…”